BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ, Peppelenbosch MP, Haagmans BL, Pan Q. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. [DOI: 10.1038/s41422-022-00618-w] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 34.0] [Reference Citation Analysis]
2 Hsu J, Hsu P, Shie C, Chuah S, Wu I, Huang W, Tang S, Tsai K, Kuo L, Ghose S, Hsu J, Shih C. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users. Medicina 2022;58:436. [DOI: 10.3390/medicina58030436] [Reference Citation Analysis]
3 Groaz E, De Clercq E, Herdewijn P. Anno 2021: Which antivirals for the coming decade? Annu Rep Med Chem 2021;57:49-107. [PMID: 34744210 DOI: 10.1016/bs.armc.2021.09.004] [Reference Citation Analysis]
4 Murayama A, Momose H, Yamada N, Matsubayashi K, Muramatsu M, Hamaguchi I, Kato T. Performance Evaluation of In Vitro Screening and Diagnostic Kits for Hepatitis C Virus Infection. Front Cell Infect Microbiol 2022;11:793472. [DOI: 10.3389/fcimb.2021.793472] [Reference Citation Analysis]
5 Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Reference Citation Analysis]